Heartburn pill may alter Body's processing of new drug

NCT ID NCT07683793

Not yet recruiting Knowledge-focused Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study looks at whether pantoprazole, a common heartburn medication, changes how the body processes an experimental drug called CHF10196. Healthy male volunteers receive CHF10196 alone and then again after taking pantoprazole. Researchers measure drug levels in the blood to check for interactions and monitor safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CHF10196 (Florensocatib) and pantoprazole
What this could lead to: If successful, this could help determine safe dosing of CHF10196 when taken with common acid-reducing drugs.
What could go wrong: This is an early-phase study in a small group of healthy men, so results may not apply to patients or predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fortrea Clinical Research Unit (CRU) Limited

Leeds, United Kingdom

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.